EUROFINS BIOPHARMA PRODUCT TESTING NORWAY AS
Keywords
researchdevelopment workbiotechnologygenomicspharmageneticsgene samplesdna sequencingdna synthesisdna deepeninggenetic engineeringproteinsmoleculespeptide sequencinglipidglycotechniqueproteomicshormonesgrowth factorscell receptorspheromonescell culturetissue culturecrossingcell fusionvaccineimmunostimulatorsembryo manipulationprocess biotechnologybioreactorsfermentationbioprocessingbiorecoverybiodesulfurizationbiological pulp productionbiofiltrationbiological regenerationsubcellular organismsgene therapyvirusesvectors
Organization
- CEO
- JR
Jan Rando1967
- Chairman of the board
- SA
Svend Aage Linde1951
- Years since formation
- 2 years
- since Sep 7, 2023
- Type
- Limited company
- VAT registered
- Yes
- Number of employees
- 0
Ownership
- Number of shares and share classes
- 30,000
- 1 share class
- Total number of shareholders
- 1
- person
Financials
- Total operating income 2024
- 1,224,824
- NOK
- Annual total result 2024
- 348,311
- NOK
- Total equity 2024
- 695,655
- NOK
Last update: Jun 17, 2025
Management
Management / administration
| Name | Role | Shares |
|---|---|---|
JR 1967 | Managing Director/CEO | - |
Board
| Name | Role | Shares |
|---|---|---|
SA 1951 | Chairman | - |
JR 1975 | Board Member | - |
MS | Board Member | - |
Others
| Name | Role | Shares |
|---|---|---|
| Auditor | - |
Last update: Jun 27, 2024
Ownership
Company shareholders
| Name | Share class | Total number of shares | Share |
|---|---|---|---|
| Ordinary shares | 30,000 | 100 % |
Last update: Jun 2, 2025
Financials
in NOK
Summary
| Year | 2024 | 2023 |
|---|---|---|
Total operating income | 1,224,824 | 312,022 |
Annual Total Result | 348,311 | 1,225 |
Total assets | 1,342,130 | 759,273 |
Total liabilities | 646,474 | 63,619 |
Total equity | 695,655 | 695,655 |
P&L
| Year | 2024 | 2023 |
|---|---|---|
Total operating income | 1,224,824 | 312,022 |
Total operating costs | 773,177 | 312,022 |
Operating result | 451,647 | 0 |
Financial income/costs | -5,095 | 0 |
Profit before tax | 446,552 | 0 |
Total tax & extraordinary income/cost | 98,241 | -1,225 |
Annual Total Result | 348,311 | 1,225 |
Balance overview
| Year | 2024 | 2023 |
|---|---|---|
Total fixed assets | 0 | 1,225 |
Total current assets | 1,342,130 | 758,048 |
Total assets | 1,342,130 | 759,273 |
Short term debt | 646,474 | 63,619 |
Long term debt | 0 | 0 |
Total liabilities | 646,474 | 63,619 |
Contributed capital | 694,430 | 694,430 |
Retained earnings | 1,225 | 1,225 |
Total equity | 695,655 | 695,655 |
Total equity and liabilities | 1,342,130 | 759,273 |
Classification
Type of organization
Limited company
Classification of institutional sector
INNL
Domestic sectors
A_IKKE-FIN
Non-financial corporations
2100
Private non-financial incorporated enterprises
Standard industrial classification
M
Main industrial area
Professional, scientific and technical activities
72
Activity
Scientific research and development
72.1
Main industrial group
Research and experimental development on natural sciences and engineering
72.11
Industrial group
Research and experimental development on biotechnology
72.110
Industrial group
Research and experimental development on biotechnology